



HbA_{1c} in Diabetes

case studies using IFCC units



Edited by Stephen Gough,
Susan Manley and Irene Stratton

HbA_{1c} in Diabetes

case studies using IFCC units

Edited by

Stephen Gough

Professor of Medicine

Institute of Biomedical Research

University of Birmingham

and Consultant Physician/Diabetologist, University Hospital

Birmingham NHS Foundation Trust

Birmingham, UK

Susan Manley

Clinical Biochemistry

University Hospital Birmingham NHS Foundation Trust

Birmingham, UK

Irene Stratton

English National Screening Programme for Diabetic

Retinopathy

Gloucestershire Hospitals NHS Foundation Trust

Cheltenham, UK



The charity for
people with diabetes



WILEY-BLACKWELL

This edition first published 2010, © 2010 by Blackwell Publishing Ltd

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

HbA1c in diabetes : case studies using IFCC units / edited by Stephen Gough, Susan Manley & Irene Stratton.
p. ; cm.

ISBN 978-1-4443-3444-9

1. Diabetes--Great Britain. 2. Glycosylated hemoglobin--Measurement. I. Gough, Stephen, Ph. D.
II. Manley, Susan, III. Stratton, Irene. [DNLM: 1. International Federation of Clinical Chemistry and Laboratory Medicine. 2. Diabetes Mellitus--blood--Great Britain. 3. Blood Chemical Analysis--Great Britain. 4. Diabetes Mellitus--blood--Great Britain--Case Reports. 5. Hemoglobin A, Glycosylated--analysis--Great Britain. WK 810 H431 2010]

RA645.D5H353 2010

616.4'62--dc22

2009046374

ISBN: 9781444334449

A catalogue record for this book is available from the British Library.

Set in 9.5/12pt Minion by Sparks – www.sparkspublishing.com

Printed and bound in Singapore by Ho Printing Singapore Pte Ltd

1 2010

Contributor list

G. Pooler R. Archbold, Consultant Chemical Pathologist, Belfast, Northern Ireland, UK

Jane Armitage, Professor of Clinical Trials and Epidemiology, Oxford, UK

Timothy G. Barrett, Professor of Paediatric Endocrinology, Birmingham, UK

Varadarajan Baskar, Consultant Physician, Wolverhampton, UK

Rikke Borg, Research Fellow, Steno Diabetes Centre, Gentofte, Denmark

Jackie Carr-Smith, Research Nurse, Birmingham, UK

Lis Chandler, Research Nurse, Birmingham, UK

Chris Cottrell, Diabetes Specialist Nurse, Llanelli, Wales, UK

Robert Cramb, Consultant Chemical Pathologist, Birmingham, UK

Steven Creely, Specialist Registrar in Diabetes and Endocrinology, Birmingham, UK

Sean F. Dinneen, Consultant Physician, Galway, Ireland

Pamela Dyson, Dietician, Oxford, UK

Julie A. Edge, Consultant in Paediatric Diabetes, Oxford, UK

Adele Farnsworth, Lead Diabetic Retinal Screener, Birmingham, UK

Valeria Frighi, Senior Clinical Researcher, University of Oxford, UK

Andrea Gomes, MSc Student, Birmingham, UK

Helen Green, Diabetes Specialist Nurse, Llanelli, Wales, UK

Sarah Griffiths, Senior House Officer in Diabetes, Birmingham, UK

Daniel Hammersley, Medical Student, London, UK

Maggie Sinclair Hammersley, Consultant Physician, Oxford, UK

Richard Haynes, Clinical Research Fellow, Oxford, UK

Simon Heller, Professor of Clinical Diabetes, Sheffield, UK

R. Welby Henry, Consultant Physician, Belfast, Northern Ireland, UK

Laura Hikin, MSc Student, Birmingham, UK

Richard I. G. Holt, Professor in Diabetes and Endocrinology, Southampton, UK

W. Garry John, Consultant Clinical Biochemist, Norfolk and Norwich University Hospitals, Norwich, UK

M. Ali Karamat, Clinical Lecturer in Diabetes and Endocrinology, Birmingham, UK

Hamza Ali Khan, Specialist Registrar, Belfast, Northern Ireland, UK

Eric S. Kilpatrick, Honorary Professor in Clinical Biochemistry, Hull, UK

R. David Leslie, Professor of Diabetes and Autoimmunity, Queen Mary University of London, UK

Nick Lewis-Barned, Consultant Physician and Senior Lecturer, Northumbria, UK

Ernesto Lopez, Medical Student, London, UK

David R. McCance, Honorary Professor of Endocrinology/Consultant Physician, Royal Victoria Hospital, Belfast, Northern Ireland, UK

John A. McKnight, Consultant Physician, Western General Hospital, and Honorary Reader, University of Edinburgh, Scotland, UK

Ciara McLaughlin, Specialist Registrar, Royal Victoria Hospital, Belfast, Northern Ireland, UK

Susan E. Manley, Clinical Scientist, Birmingham, UK

Sally M. Marshall, Professor of Diabetes, Newcastle upon Tyne, UK

Sarah Moore, GP, Worcestershire, UK

Joanne Morling, Specialty Registrar in Public Health, University of Edinburgh, Scotland, UK

Parth Narendran, Clinical Senior Lecturer and Honorary Consultant in Diabetes, Birmingham, UK

Ailish G. Nugent, Consultant Physician, Belfast, Northern Ireland, UK

Máire O'Donnell, Research Associate, Galway, Ireland

Katharine R. Owen, Clinician Scientist, Oxford, UK

Richard Paisey, Consultant Physician, Torbay, UK

Stuart A. Ritchie, Specialist registrar, Edinburgh, Scotland, UK

Jonathan Roland, Consultant Diabetologist, Peterborough, UK

Rachel Round, Researcher, Birmingham, UK

Peter H. Scanlon, Consultant Ophthalmologist, Cheltenham and Oxford, UK

Ken Sikaris, Director of Chemical Pathology, Melbourne Pathology, Victoria, Australia

Janet Smith, Honorary Consultant Clinical Scientist, University Hospital Birmingham, UK/Honorary Senior Clinical Lecturer, Medical School, University of Birmingham, UK

Matthew Stephenson, Consultant Psychiatrist in Learning Disability, Oxford Learning Disability NHS Trust, Oxford, UK

Roy Taylor, Professor of Medicine and Metabolism, Newcastle upon Tyne, UK

Athinyaa Thiraviaraj, Specialist Registrar, Belfast, Northern Ireland, UK

Tara Wallace, Consultant Physician, Norfolk and Norwich University Hospitals, Norwich, UK

Jonathan Webber, Consultant Physician, Birmingham, UK

Amanda Webster, Genetic Diabetes Specialist Nurse, Oxford, UK

Rob Willox, Retinal Screening Technician, Torbay, UK

Alex Wright, Consultant Physician, Walsall/Birmingham, and Honorary Senior Lecturer, Birmingham, UK

You Yi Hong, Surgical Intern, Galway, Ireland

Preface

The measurement of HbA_{1c} is a key tool in the treatment of diabetes mellitus. For health care professionals involved in the management of diabetes in the UK there is an additional complication, between 2009 and 2011, with a change of HbA_{1c} units. The old DCCT percentage is giving way to the internationally recognised IFCC units of mmol/mol in 2011.

To further the understanding of HbA_{1c} measurements, we have summarised the important issues and then appended a number of case studies involving a wide range of patients from children to the elderly, showing the measurements in both the 'old' and 'new' units. These cover a wide range of diabetes-related conditions and describe the treatment plans and follow-up. We hope that this book will be a useful resource for all those involved in diabetes care as they come to terms with IFCC reporting.

This cannot be the last word on the measurement or role of HbA_{1c} and we look forward to continuing the interaction with colleagues in the UK and further afield.

*Stephen Gough, Susan Manley, Irene Stratton
Birmingham, UK*

Acknowledgements

We are most grateful to all the contributors who have given us the benefit of their experience and to their patients, and also to Professor Sir George Alberti and Diabetes UK for their endorsement of the book. We also wish to thank Vivienne Kendall for assembling the case studies, Alison Barratt for designing the cover and the staff at Wiley-Blackwell for their help with the editorial and production processes. In addition, we thank Keith Chambers, Jonathan Middle, Peter Nightingale, Marco Ossani, Francesco Pessala, Janet Smith and the biomedical scientists at University Hospital Birmingham NHS Foundation Trust. We acknowledge receipt of a grant from the Novo Nordisk Educational Research Foundation for our research study, the NOVO GFH (glucose, fructosamine and HbA_{1c}) Study.

The following have kindly given their permission for us to use previously published material:

Rikke Borg (Figure 2); Keith Chambers (Figure 5); Rury Holman (Figure 6; unpublished and reproduced with permission); *The Lancet* (1998) 352, 837–53 and *NEJM* (2008) 359, 1577–89 (Figures 7A and B); *BMJ* (2000) 321, 405–12 (Figure 8); *NEJM* (1993) 329, 977–86 (Figure 9); *Diabetic Medicine* (2009) 26,115–21 (Figure 10); Ken Sikaris (Figure 11); *Diabetes Care* (2008) 31, 1473–78 (Figure 12); poster from the GFH Study at IDF 2009 (Figure 14); Garry John (Figure 15; unpublished and reproduced with permission); *UK Office of Public Sector Information: Health Technology Assessment* (2000) 4 (3); Reproduced under the terms of Click Use PSI Licence C2009002437 (Figure 16); Clinical Biochemistry, University Hospital Birmingham NHS Foundation Trust (Figure 17); *Ann Clin Biochem* (2006) 43, 135–45. Copyright (2006) Royal Society of Medicine Press, UK (Figure 18); Jonathan Middle, NEQAS (Figure 19); Becton Dickinson (Figure 20); Medtronic (Figure 21); plates reproduced with permission from patients, the South Devon Healthcare Trust and the Gloucestershire Hospitals NHS Foundation Trust. Our thanks also to Judith Kuenen for help in developing Table 1.

Foreword

The relation of glycated haemoglobin to blood glucose levels was first discovered about 40 years ago. Over the next decade assays were developed to allow its routine use. It was a massive breakthrough for people with diabetes and health professionals, as for the first time there was an independent way of assessing average blood glucose levels over a period of several weeks. The test was first used for assessing control in 1976, and a wide range of different tests were developed. Some of these were cumbersome; many gave different values and it was not until the DCCT trial that an effort was made to standardise reporting. Since then, many laboratories worldwide align their results against the DCCT standard. The results have traditionally been presented as a percentage of total haemoglobin.

In the interim, the IFCC has developed a new standard and reference method against which other methods can be standardised, and absolute amounts of HbA_{1c} can be measured. As a result the recommendation now is that results should be presented as mmol glycated haemoglobin/mol unglycated haemoglobin. The UK is following this recommendation; parallel reporting is now in place and will continue until mid-2011. Obviously the numbers are different and it will take time for professionals and patients to attune themselves to the new units. This is of course not a new problem. Thirty-five years ago, most clinical biochemistry results were changed from a weight-based system to a molar system, and many analytes – including glucose – showed large changes in the actual numbers reported. The switch, backed by a strong educational program and initial double reporting, was relatively trouble-free.

The same should be true for HbA_{1c} . The current volume is an excellent adjunct to the educational process – and a novel and readable way of helping people. A series of case studies is presented, in which both ways of expressing HbA_{1c} are used. This covers a wide range of values and through repetition, the numbers start to become more familiar and make sense.

*KGMM Alberti
St Mary's Hospital, London*

List of abbreviations

AA	Normal haemoglobin
AC	Haemoglobin C trait
ACB	Association for Clinical Biochemistry
ACD	Antihypertensive ACD algorithm
ACE	Angiotensin-converting enzyme
ACR	Albumin creatinine ratio
ACTH	Adrenocorticotrophic hormone
AD	Haemoglobin D trait
ADA	American Diabetes Association
ADAG	A1C-derived average glucose
AE	Haemoglobin E trait
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
ARB	Adrenergic receptor blocker
AS	Sickle cell trait
A1C	HbA _{1c}
BHS	British Hypertension Society
BM	Blood glucose strips
BMI	Body mass index
CGM	Continuous blood glucose monitoring
CSII	Continuous subcutaneous insulin infusion
DCCT	Diabetes Control and Complications Trial
DIGAMI	Diabetes Mellitus, Insulin–Glucose Infusion in Acute Myocardial Infarction
DM	Diabetes mellitus
DUK	Diabetes UK
DVT	Deep vein thrombosis
eAG	Estimated average glucose
EASD	European Association for the Study of Diabetes
ECG	Electrocardiogram
EDTA	Ethylenediamine tetraacetic acid
eGFR	Estimated glomerular filtration rate
FBG	Fasting blood glucose
FPG	Fasting plasma glucose
FSH	Follicle stimulating hormone
GAD	Glutamic acid decarboxylase
GFH	Glucose Fructosamine HbA _{1c} (research study)

Hb	Haemoglobin
HbA _{1c}	Glycated haemoglobin
HbF	Fetal haemoglobin
HDL	High-density lipoprotein
HNF1A	Hepatic nuclear factor 1A
HPLC	High performance liquid chromatography
IDF	International Diabetes Foundation
IFCC	International Federation of Clinical Chemistry and Laboratory Medicine
IFG	Impaired fasting glucose
IGF-1	Insulin-like growth factor 1
IGT	Impaired glucose tolerance
JDS	Japanese Diabetes Society
LDL	Low-density lipoprotein
LH	Luteinising hormone
MODY	Maturity onset diabetes of the young
MRI	Magnetic resonance imaging
NGSP	National Glycohemoglobin Standardization Program
NICE	National Institute for Health and Clinical Excellence
OGTT	Oral glucose tolerance test
PCI	Percutaneous coronary intervention (angioplasty)
POCT	Point of care testing
RPG	Random plasma glucose
SI	Système Internationale
SMBG	Self monitoring of blood glucose
SS	Sickle cell disease/anaemia
T ₄	Thyroxine
TSH	Thyroid-stimulating hormone
UKPDS	UK Prospective Diabetes Study
VA	Visual acuity
WHO	World Health Organisation
2hPG	2 hour plasma glucose
³² P	Radioactive isotope of phosphorus

Contents

Contributor list	v
Preface	viii
Acknowledgements	ix
Foreword	x
List of abbreviations	xi
Introduction	1

Case studies

1: Diagnosis and early management of type 1 diabetes in a young child	29
2: Management of an elderly patient, housebound and living alone	30
3: Gestational diabetes	31
4: Weight loss and improved glycaemic control	32
5: Type 2 diabetes in a child	33
6: Weight reduction	34
7: Improved glycaemic control	35
8: Risk of hypoglycaemia in a patient in a unit for the elderly mentally ill in a nursing home	36
9: Structured education for type 1 diabetes	37
10: Woman with family history of raised cholesterol and diabetes	38
11: Type 1 diabetes in a child	39
12: Poor glucose control with microvascular complications	40
13: Renal failure and cardiovascular disease in an Asian patient	41
14: Type 1 diabetes in a teenage girl concerned about weight	42
15: Glycaemic control through patient empowerment	43
16: Diagnosis and early management of type 2 diabetes in patient with acute coronary syndrome	44
17: Incretin or insulin?	45
18: Type 2 diabetes and pregnancy	46
19: Deterioration of pre-existing diabetes in a patient on low dose quetiapine	47
20: Low HbA _{1c} and risk of hypoglycaemia	48
21: Rapid changes in glycaemic control and retinopathy	49

22: Type 1 diabetes in a young man moving from paediatric to young adult services	50
23: Monitoring glycaemic control: HbA _{1c} or fructosamine	51
24: Prepregnancy and pregnancy in type 1 diabetes	52
25: Maturity onset diabetes of the young, subtype <i>HNFI1A</i> (<i>HNFI1A</i> -MODY)	53
26: 'Overtreating' type 2 diabetes	54
27: Diabetes and an elevated triglyceride concentration	55
28: Multiple therapies leading to bariatric surgery	56
29: Optic neuropathy	57
30: Uncertainty around the estimate of average plasma glucose from HbA _{1c}	58
31: Antipsychotics	59
32: Abnormal liver function in a patient with type 2 diabetes	60
33: Fructosamine in diabetic nephropathy	61
34: Recurrent hypoglycaemia caused by secondary adrenal insufficiency	62
35: A patient with diabetes taking niacin	63
36: Tight glycaemic control leading to nocturnal hypoglycaemia	64
37: Diabetes and iron-deficiency anaemia	65
38: Deterioration in vision after commencing insulin treatment: the early worsening phenomenon	66
39: Type 1 diabetes – worsening glycaemic control on introduction of a pump?	67
40: Monitoring glycaemic control in a patient with sickle cell trait	68
41: Balancing fear of hypoglycaemia with optimal control in pregnancy	69
42: Asian patient with high-risk feet and suboptimal glycaemic control	70
43: Type 2 diabetes and polycystic ovarian syndrome	71
44: Impact of variant haemoglobin AC on HbA _{1c} determination	72
45: Diabetic nephropathy	73
Colour plates related to case studies 29 and 38	75
Thermometer relating HbA _{1c} to the complications of type 2 diabetes	76
Conversion table for HbA _{1c} from IFCC to DCCT-aligned units	76

Introduction

Background

What is diabetes?

Impairment of glucose regulation in the body leads to diabetes. In untreated diabetes, glucose levels in the blood increase. In type 1 diabetes, mainly found in children and young adults, β -cells in the islets of Langerhans of the pancreas fail to secrete insulin and insulin replacement is required.

In people with type 2 diabetes, typically diagnosed in middle age but now also in children, blood glucose levels rise as a result of both resistance to the action of insulin and also progressive β -cell dysfunction (Figure 1). In type 2 diabetes, treatment involves lifestyle changes and oral antidiabetes drugs that lead to an increase in insulin secretion from the pancreas or increased insulin sensitivity in the tissues. Injectable treatments may also be required, with the majority of people with type 2 diabetes ultimately requiring insulin.

Despite defects in the secretion and action of insulin being the cause of diabetes, the hormone is rarely measured in routine clinical care, although it can be measured easily on automated equipment in pathology laboratories. A reference method using mass spectrometry has been developed for calibration, so that in-




Figure 1 Development of type 2 diabetes over time.

sulin values obtained from different methods will be comparable. Blood glucose control is usually monitored in patients by determination of HbA_{1c} – a measure of glucose-bound (glycated) haemoglobin. This is proportional to the amount of glucose in the blood over the previous two to three months, the lifespan of red blood cells. Lowering blood glucose levels will lead to lower HbA_{1c} and failure to control blood glucose successfully, to high HbA_{1c}. Glycated haemoglobin has been used for assessing glycaemic control since 1976.

The prevalence of diabetes, particularly type 2, is increasing inexorably – putting a significant strain on healthcare resources that will impact most on developing regions of the world. Many of the ethnic groups that will be affected (e.g. those in India, China and Africa) are more susceptible to diabetes than Caucasians. Lifestyle is also a major factor: the likelihood of developing diabetes is increased when exercise levels are reduced and high calorific diets adopted, leading to overweight or obesity. These changes are typically related to urbanisation, industrialisation and the adoption of a western lifestyle.

The concentration of glucose in blood varies according to the time of the day and reflects the patient's nutritional intake and ability to metabolise glucose (Figure 2). In practice, blood is collected by health care professionals, with glucose measured at any time of the day (random plasma glucose, RPG), or at a pre-arranged time after fasting (fasting plasma glucose, FPG). Plasma glucose values are sometimes recorded at specified times, e.g. two hours after a meal or the time of the last meal is recorded.

Smaller differences occur in glucose levels when blood is obtained from various sites of the body or when different devices are used for measurement. Blood can be taken from veins (venous), finger pricks (capillary), the abdomen (interstitial) or arteries (arterial). To monitor their glucose control, patients may test their own blood using meters or implanted sensors. For medical review, they can have blood samples taken in a clinical setting, with measurement at point of care or in a central laboratory.

What is HbA_{1c}?

Glycation of haemoglobin is not catalysed by enzymes, but occurs through a chemical reaction that depends on the exposure of red blood cells to glucose circulating in the blood (Figure 3). Clinical management of diabetes involves regular measurement of HbA_{1c} to monitor the glucose level in the bloodstream. HbA_{1c} is usually measured at three- or six-monthly intervals or at the time of an annual review. One of the advantages of measuring HbA_{1c} rather than glucose is that fasting is not required. Although a venous blood sample is required routinely by most laboratories, HbA_{1c} can also be measured on capillary blood obtained from a finger prick, using smaller analysers located at point of care.

Any event or condition that affects haemoglobin, or red blood cells or their turnover may affect the amount of HbA_{1c} in circulating blood. Measurement of reticulocytes (immature red blood cells) will determine whether the turnover of red blood cells is affected; if it is accelerated, the reticulocyte count will be




Figure 2 Daily profile from implanted continuous blood glucose monitoring device in (A) person without diabetes; (B) person with well-controlled type 1 diabetes.




Figure 3 Formation of HbA_{1c}.

high. Some anaemias, e.g. haemolytic anaemia and polycythaemia rubra vera can depress HbA_{1c}, because the lifespan of the red blood cells is shorter than normal. Abnormal or variant haemoglobins may also affect HbA_{1c} results, as discussed later.

The haemoglobin molecule is composed of four globin protein chains, each with a haem moiety, held together by non-covalent interactions (Figure 4). The 3D structure of the molecule changes when oxygen binds to the haem. In normal adult haemoglobin (HbA), there are 2 α globin chains of 141 amino acids each, coded by DNA on chromosome 16, and 2 β globin chains of 146 amino acids coded on chromosome 11. Fetal haemoglobin, present in babies, binds oxygen with a greater affinity than adult haemoglobin; it contains 2 α chains and 2 γ chains coded on chromosome 11. The γ chain has less positive charges than the adult β chain. Over the first year of life, the production of fetal haemoglobin ceases so that it accounts for less than one per cent of haemoglobin in adults (Figure 5). In certain circumstances due to genetic abnormalities, higher amounts of fetal haemoglobin occur in adults (termed hereditary persistence of fetal haemoglobin) which can lead to problems when using HbA_{1c} to monitor glucose control in diabetes.




Figure 4 Structure of haemoglobin molecule.